-
Health todayObesity, diabetes and GLP-1 new
Consistent glucose monitor users stayed on GLP-1 drugs longer in type 2 diabetes
In US claims for adults with type 2 diabetes starting a GLP-1 drug, 68.4% of consistent glucose monitor users were still on it at one year, against 51.9% of non-users.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
Type 2 diabetes fell by a quarter among Australian sleeve gastrectomy patients
Among 34,738 adults undergoing sleeve gastrectomy in New South Wales from 2017 to 2022, type 2 diabetes prevalence fell by 24.4%, and 72.3% had at least one cardiovascular risk factor.
Peer-reviewed -
Health todayHeart and stroke new
Atrial fibrillation recurrence after ablation was similar on GLP-1, SGLT2 or both
Among adults having catheter ablation for atrial fibrillation, recurrence was similar on a GLP-1 drug, an SGLT2 inhibitor or both, while all-cause mortality was lower on the combination.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 confirms
GLP-1/GIP agonist BGM0504 reduced weight by up to 18% at 24 weeks
In 120 Chinese adults with overweight or obesity and no diabetes, weekly BGM0504 reduced weight by 10.7% to 18.3% at 24 weeks, as compared to no change on placebo.
Peer-reviewed -
Behavioural scienceAdherence and persistence confirms
Most US adults starting a GLP-1 obesity drug stop within the year
Among 201,229 insured US adults with obesity and no diabetes starting a GLP-1 drug, 30.7% stayed on it for most of the following year, as did 20.3% of paediatric patients.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
Adults with diabetes lost more muscle after starting a GLP-1 drug
In the German National Cohort, adults with diabetes who started a GLP-1 drug lost 2.75 percentage points more skeletal muscle volume than matched adults who did not.
Preprint · not peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
Diabetes was more common in older US influenza deaths than in COVID-19 deaths
Among US inpatients aged over 65 who died, 46.6% of those dying of COVID-19 had diabetes, as compared to 63.1% of those dying of influenza.
Peer-reviewed -
Health todayCancer refines
Pancreatic cancer risk on GLP-1 drugs depends on the diabetes drug compared
Pancreatic cancer was less common in GLP-1 starters than in starters of four other diabetes classes, while against insulin the paper reports a lower hazard but a higher absolute risk.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 confirms
GLP-1 drugs cut weight by 6.7 kg in patients taking antipsychotics
A meta-analysis of eight randomised trials in 664 patients taking antipsychotics found that GLP-1 receptor agonists reduced body weight by 6.74 kg, alongside more nausea, vomiting and constipation.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
GLP-1 drugs did not reduce new sleep apnoea diagnoses in UK diabetes patients
Among UK adults with type 2 diabetes and obesity, those starting a GLP-1 drug rather than a weight-neutral DPP-4 inhibitor had no fewer new sleep apnoea diagnoses (hazard ratio 1.07).
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
Adults with obesity and asthma on GLP-1 drugs had fewer recorded exacerbations
In 2,423 matched pairs of adults with obesity and asthma, one-year recorded asthma exacerbation was 1.7% on GLP-1 therapy as compared to 4.0% on other weight-management drugs.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
Review sets out why bone is lost during weight loss
Weight loss raises bone turnover and lowers bone mineral density, with greater loss in older and leaner adults and after severe caloric restriction such as incretin mimetics or bariatric surgery.
Peer-reviewed